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Abstract
Background: The anti-HCV antibody response has not been well characterized during the early phase of HCV
infection and little is known about its relationship to the clinical course during this period.
Methods: We analyzed serial anti-HCV antibodies longitudinally obtained from a prospective cohort of 65 patients
with acute HCV infection by using a microparticle enzyme immunoassay AxSYM HCV 3.0 (Abbott Diagnostics)
during the first 12 months from HCV acquisition in Rio de Janeiro, Brazil. Spontaneous viral clearance (SVC) was
defined as undetectable HCV RNA in serum, in the absence of treatment, for three consecutive HCV PCR tests
within 12-months of follow-up.
Results: Baseline antibody values were similar among patient groups with self-limiting HCV evolution (n = 34) and
persistent viremia (n = 31) [median (interquartile range) signal/cut-off ratio (s/co) 78.7 (60.7-93.8) vs. 93.9 (67.8-
111.9), p = 0.26]. During 12-months follow-up, patients with acute spontaneous resolving HCV infection showed
significantly lower serial antibody response in comparison to individuals progressing to chronic infection [median
(interquartile range) s/co 62.7 (35.2-85.0) vs. 98.4 (70.4-127.4), p < 0.0001]. In addition, patients with self-limiting HCV
evolution exhibited an expeditious, sharp decline of serial antibody values after SVC in comparison to those
measured before SVC [median (interquartile range) s/co 56.0 (25.4-79.3) vs. 79.4 (66.3-103.0), p < 0.0001].
Conclusion: Our findings indicate a rapid short-term decline of antibody values in patients with acute
spontaneous resolving HCV infection.
Background
Acute hepatitis C virus (HCV) infection accounts for
approximately 20% of cases of acute hepatitis today,
with an estimated 30,000 to 40,000 new cases occurring
every year in the United States alone. Worldwide at
least 170 million individuals are chronically infected
with HCV [1-4]. The natural history of HCV infection is
heterogeneous and incorporates a range of prognostic
determinants [1-6]. Untreated, acute HCV infection
progresses to chronic infection in 50-80% of patients
[7-9]. Rates of spontaneous HCV resolution (SVC)
reported from prospective studies substantially vary,
with estimates ranging from 10 to 60% [2-6,10,11].
As acute HCV infection is clinically inapparent in
most cases, longitudinal data on the natural course of
early disease remain sparse [12] with the immunologic
correlates of spontaneous recovery being poorly under-
stood [13]. While antibodies detected by commercially
available tests, have been widely used for diagnosing
HCV infection, there is little information on the timing,
magnitude, specificity and clinical relevance of the anti-
body dynamics during acute HCV infection, and its rela-
tion to short-term disease outcome widely remains
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follow-up data on serial antibody values in a Brazilian
cohort of 65 patients with acute HCV infection, fol-
lowed prospectively from the initial phase, between 2001
and 2009. We compared longitudinal patterns of anti-
body ratios between individuals with self-limiting acute
HCV evolution and patients progressing to chronic
infection.
Methods
We have recently published the results of an acute HCV
cohort in Rio de Janeiro, Brazil [20], which showed an
independent relationship of peak anti-HCV antibody
levels and disease outcome. However, in this study we
extended the study prospectively to 12 months and used
serial anti-HCV antibody ratios obtained from a com-
mercial microparticle enzyme immunoassay (MEIA)
AxSYM HCV 3.0 (Abbott Laboratories) and serial quali-
tative HCV RNA detected by the Cobas Amplicor
Monitor HCV test (Roche Diagnostics) for analysis.
Patients who did not clear HCV RNA during early fol-
low-up were referred for antiviral therapy. Six of the
patients in the present study underwent antiviral treat-
ment within the first 12 months from infection and
their anti-HCV antibody ratios were not considered for
analysis during and after the treatment period. A more
detailed description of the program methodology and
study cohort has been reported previously [20].
This study was approved by the Research on Human
Subjects Ethics Committee of the Oswaldo Cruz Foun-
dation as well as the Brazilian National Research Ethics
Commission. Signed informed consent was obtained
from all participants.
Laboratory Methods
Following diagnosis of acute HCV infection, samples were
obtained from study participants at approximately every
two weeks for the first, second and third month and then
monthly from the fourth month to one year between 2001
to 2009. Overall 85% of scheduled blood draws were
obtained. Serum samples obtained serially were aliquoted
for serological and molecular testing and stored at -80°C.
Samples were thawed only once for laboratory testing.
Repeat tests were performed for anti-HCV antibody testing
or HCV RNA detection on separate samples obtained at
t h es a m et i m ep o i n t .A n t i - H C Va n t i b o d yt e s t i n gr e s u l t s
were obtained from ratios between sample absorbance and
the calculated cut-off for each sample (s/co) with the auto-
mated MEIA AXSYM HCV 3.0. The qualitative determina-
tion of HCV RNA was carried out by the Cobas Amplicor
Monitor HCV test (Roche Diagnostics) which has a detec-
tion limit of 50 IU/ml. First time samples that were HCV
RNA undetectable by the Cobas Amplicor Monitor were
retrospectively reevaluated by the VERSANT HCV RNA
Qualitative Assay (TMA) (Siemens Healthcare Diagnostics)
with a lower detection limit of 9.6 IU/ml.
Definitions
Diagnosis of acute HCV infection was based upon pre-
viously established criteria [10,11,21]: (1) a positive anti-
HCV antibody or HCV RNA result in a patient with a
negative anti-HCV test result within the past year, or (2)
a positive anti-HCV and HCV RNA result in a patient
with clinical hepatitis, ALT levels 10 times the upper
limit of normal (32 U/L); or, (3) in absence of detectable
HCV RNA, history of high-risk exposure between 1 and
3 months prior to clinical manifestation in anti-HCV
seropositive patients. Further details on the diagnosis of
acute HCV infection is described elsewhere [20]. To
estimate the date of HCV infection the day of high-risk
exposure was used, or, when unavailable, as either 6
weeks before the onset of symptoms in symptomatic
patients [7,10], or 6 weeks before seroconversion in
asymptomatic patients [10,15].
Spontaneous viral clearance (SVC) was defined as
undetectable HCV RNA in serum within the first 12
months of follow-up after the estimated date of infec-
tion, in the absence of treatment. Since oscillations in
HCV RNA detection are frequently observed in the
early phase of HCV infection, two additional consecutive
negative HCV RNA test results were required to sustain
SVC classification [22,23]. The midpoint between the
date of the first of three consecutive RNA-negative sam-
ples and the date of the last positive HCV RNA was
used as the estimated date of SVC. For six patients with
undetectable HCV RNA in the first sample collected,
the date of SVC was estimated as the midpoint between
the date of infection and the date of the first undetect-
able HCV RNA sample [10,11].
Statistical Analysis
Inter-individual differences in baseline antibody values
(i.e. measurements at first visit) and median antibody
values during prospective 12-months follow-up between
patients with self-limiting and chronic HCV evolution
were assessed using independent samples t-test. Serial
patterns of longitudinal antibody values between patient
groups were analyzed by means of linear mixed-effects
regression models, utilizing intra-individual differences
and multiple measurements per patient over time. Two-
sided p-values < 0.05 were considered statistically signif-
icant. All analyses were performed using STATA 10.0
and SAS 9.1 statistical software.
Results
Patient characteristics
40 women (61.5%) and 25 men (38.5%) comprised the
cohort eligible for analysis. Mean age at HCV infection
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(83.1%) experienced disease symptoms (including jaun-
dice and/or dark urine) during follow-up. During the
12-month follow-up 439 serial antibody measurements
were obtained (median per patient 6.0, range 1-16).
Antibody values were approximately normally distribu-
ted, with a sample absorbance/cut-off ratio (s/co) ran-
ging from 0.4 to 185.6. After 12 months of follow-up,
34/65 patients (52.3%) had spontaneously recovered
from acute HCV, including 5 with clearance after six
months of follow-up. A detailed comparison of sociode-
mographic and clinical characteristics between indivi-
duals with acute spontaneous resolving HCV infection
and patients’ progression to chronic infection has been
previously reported by our group [20].
Longitudinal Antibody Response and Spontaneous HCV
Clearance
Baseline antibody ratios were similar among patient
groups with self-limiting HCV evolution (n = 34) and per-
sistent viremia (n = 31) [median (interquartile range -
IQR) s/co ratio 78.7 (60.7-93.8) vs. 93.9 (67.8-111.9), p =
0.26, Table 1]. Compared to patients with persistent vire-
mia, patients with self-limiting HCV evolution had signifi-
cantly lower median and serial antibody ratios [105.5 s/co
(IQR 75.4-123.6) vs. 66.2 s/co (IQR 47.8-79.5), p < 0.0001,
and 98.4 s/co (IQR 70.4-127.4) vs. 62.7 s/co (IQR 35.2-
85.0), p < 0.0001, Table 1]. In addition, patients with self-
limiting HCV infection showed a significant and sharp
decline of serial antibody ratios after SVC [79.4 s/co (IQR
66.3-103.0) before SVC vs. 56.0 s/co (IQR 25.4-79.3) after
SVC, p < 0.0001, Table 1].
Discussion
We present the antibody dynamics during the initial
phase of disease in 65 individuals with acute HCV infec-
tion, prospectively followed in Rio de Janeiro, Brazil.
Although different profiles of long-term humoral
immune response between spontaneous clearers and
chronic carriers have previously been described in HCV
infection [13,17-19,24,25], the dynamics of humoral
responses during the acute phase of infection are less
well documented due to the fact that acute HCV
cohorts and prospective data from the early phase of
disease are rare [12]. Our previous study had demon-
s t r a t e dt h a tl o wl e v e l so fa n t i - H C Va r ep r e d i c t i v eo f
spontaneous viral clearance in the acute phase of infec-
tion in patients followed during a 6-month period. This
study, however, in extending the study to a 12-month
time period, identified an additional 5 cases of SVC and
shows that longitudinal antibody response may be used
as a predictor of spontaneous viral during early phase of
HCV infection when rapid declines in anti-HCV antibo-
dies occur. From a clinical standpoint, two or more
s e r i a lv a l u e sm a yb em o r ef e a s i b l et h a ne x a m i n i n gp e a k
antibody values [20] as a discriminator of outcome.
Takaki and colleagues [13] analyzed the HCV-specific
humoral immune responses in patients infected with
HCV over an 18-20 year course of infection after docu-
mented exposure and found that a large number of
patients with viral clearance tested negative for anti-
HCV antibodies. Messick and colleagues [24] studied a
cohort of haemophiliacs exposed to HCV infection and
observed significant decrease in anti-HCV antibody
ratios in patients with viral clearance when compared to
those with persistent viremia over a period of 15 years.
Lu and co-workers [25], described persistently low anti-
body s/co ratios in subjects with spontaneous viral reso-
lution, suggesting that antibody ratios might not rise
significantly in those who spontaneously recover.
It has been speculated that the partial or total loss of
anti-HCV antibodies in immunocompetent patients that
have spontaneously recovered from HCV may be attrib-
uted to the lack of HCV antigen that would sustain anti-
body levels [24,26]. Studies in chimpanzees have already
shown that low doses of HCV inoculum may promote
cellular immune responses in chimpanzees but rarely
produce detectable viremia or seroconversion [27].
Cross-sectional studies have additionally demonstrated
that indeterminate and weak antibody reactivity are each
Table 1 Anti-HCV antibodies (s/co) during first 12 months of follow-up in 65 patients with acute HCV infection,
stratified according to viral clearing status, Rio de Janeiro, Brazil, 2001-2009
a
Anti-HCV Antibodies (s/co) SVC
b (n = 34) Non-SVC (n = 31) p-value SVC vs.
Non-SVC
p-value before
SVC vs. after SVC
Total Before SVC After SVC
At Baseline/First Visit 78.7 (60.7-93.8) n.a.
c n.a. 93.9 (67.8-111.9) 0.26 n.a.
Median during follow-up 66.2 (47.8-79.5) 71.0 (55.8-80.0) 55.1 (17.9-71.8) 105.5 (75.4-123.6) <0.0001 0.04
Serial during follow-up
d 62.7 (35.2-85.0) 79.4 (66.3-103.0) 56.0 (25.4-79.3) 98.4 (70.4-127.4) <0.0001 <0.0001
a Data given as median (interquartile range).
b Spontaneous Viral Clearance (SVC) was defined as a series of at least 3 negative HCV RNA results within 12 months after the estimated point of infection.
c n.a. denotes not applicable.
d All anti-HCV antibody measures per patient during the first 12 months from the estimated date of infection were considered and weighted equally.
P-value for group comparison calculated from linear-mixed effects regression.
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Our data provide additional information regarding the
timing of emergence of this antibody pattern, showing
that the HCV-specific humoral immune response
declines early after clearance, once antigenic stimulus is
removed.
Our study does have potential limitations that should
be considered. First, patients in our cohort were predomi-
nantly symptomatic and of female sex, with both charac-
teristics previously being shown to be associated with
favourable outcome in acute HCV infection [6]. Second,
exact date of exposure was not available for all patients
and had to be estimated on the basis of established cri-
teria. However, sensitivity analyses previously conducted
by our group [20] indicated that the impact of this limita-
tion is negligible. Finally, sample size eligible for the pre-
sent analyses was relatively small and time periods
between prospective follow-up visits and numbers of
serial antibody measures varied among study participants,
preventing us from evaluating antibody responses at uni-
form time points for all patients during follow-up.
Conclusions
Our data indicate a rapid short-term decline of antibody
values in patients with acute spontaneous resolving
HCV infection, with the dynamics of this decline being
significantly faster than previously appreciated. These
findings suggest that HCV antibody testing performed
years after infection might be less reliable than currently
thought as a marker for HCV exposure, with underesti-
mation of the rate of HCV infection and spontaneous
clearance. Serial anti-HCV antibody ratio measurements
may also distinguish outcome and could be useful for
prognosis in settings where HCV RNA testing is una-
vailable or constrained by resource limitations.
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